p53 gene mutation in colorectal carcinoma

被引:0
作者
Roa, JC
Roa, I
Melo, A
Araya, JC
Villaseca, MA
Flores, M
Schneider, B
机构
[1] Univ La Frontera, Fac Med, Lab Biol Mol, Temuco, Chile
[2] Univ La Frontera, Unidad Anat Patol, Temuco, Chile
[3] Univ La Frontera, Serv & Dept Cirugia, Temuco, Chile
[4] Univ La Frontera, Hosp Reg Temuco, Temuco, Chile
关键词
carcinoma; colonic neoplasms; p53; gene; mutation; rectal neoplasms;
D O I
暂无
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Background Genetic events associated to colorectal carcinoma are well characterized, but there is scanty information about this issue in Chilean subjects. Aim: To determine the frequency and distribution of exons 5, 6, 7, 8 and 9 mutations and the immunohistochemical expression of p53 gene in biopsy samples of colorectal carcinoma. Material and methods: p53 gene exons 5, 6, 7, 8 and 9 were directly sequenced in 42 biopsy samples of colorectal carcinoma. Immunohistochemical expression of p53 was determined in 35 samples. Results: Thirty one discrete mutations (12 transitions, 11 transversions and 8 insertions) were observed in 21 samples (60%). Nine samples had mutations in exon 5, twelve samples had mutations in exon 6, seven samples had mutations in exon 7 and three samples had mutations in exons 8 and 9. Immunohistochemical expression of p53 protein was observed in 18 of 35 cases. There was a high correlation between the genetic alteration and immunohistochemistry, when p53 was expressed in more the 20% of cells. The positive and negative predictive values of p53 expression were 87 and 80% respectively. There was a non significant lower mortality among patients with mutations in their biopsies. Conclusions: These results confirm the involvement of p53 gene mutations in colonic carcinogenesis. Immunohistochemical methods for the detection of p53 protein have a high predictive value.
引用
收藏
页码:996 / 1004
页数:9
相关论文
共 40 条
[31]   P53 IN COLORECTAL-CANCER - CLINICOPATHOLOGICAL CORRELATION AND PROGNOSTIC-SIGNIFICANCE [J].
SCOTT, N ;
SAGAR, P ;
STEWART, J ;
BLAIR, GE ;
DIXON, MF ;
QUIRKE, P .
BRITISH JOURNAL OF CANCER, 1991, 63 (02) :317-319
[32]  
Smith D. R., 1994, Annals Academy of Medicine Singapore, V23, P803
[33]  
TAMURA G, 1991, CANCER RES, V51, P3056
[34]  
TSONGALIS GJ, 1994, CLIN CHEM, V40, P485
[35]  
VAN MEIR EG, 1994, CANCER RES, V54, P649
[36]   Design and application of 2-D DGGE-based gene mutational scanning tests [J].
Van Orsouw, NJ ;
Vijg, J .
GENETIC ANALYSIS-BIOMOLECULAR ENGINEERING, 1999, 14 (5-6) :205-213
[37]   Double immunostaining for p53 and molecular chaperone hsp72/73 in gastric carcinoma [J].
Villaseca, MA ;
Roa, I ;
Araya, JC ;
Roa, JC ;
Flores, P .
JOURNAL OF CLINICAL PATHOLOGY-MOLECULAR PATHOLOGY, 1997, 50 (06) :317-321
[38]   ASSOCIATION OF HUMAN PAPILLOMAVIRUS TYPE-16 AND TYPE-18 E6 PROTEINS WITH P53 [J].
WERNESS, BA ;
LEVINE, AJ ;
HOWLEY, PM .
SCIENCE, 1990, 248 (4951) :76-79
[39]   Fluorescence in situ hybridization analysis of HER-2/neu, c-myc, and p53 in endometrial cancer [J].
Williams, JA ;
Wang, ZR ;
Parrish, RS ;
Hazlett, LJ ;
Smith, ST ;
Young, SR .
EXPERIMENTAL AND MOLECULAR PATHOLOGY, 1999, 67 (03) :135-143
[40]   P53 IN TUMOR PATHOLOGY - CAN WE TRUST IMMUNOCYTOCHEMISTRY [J].
WYNFORDTHOMAS, D .
JOURNAL OF PATHOLOGY, 1992, 166 (04) :329-330